title: miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan.
abstract: OBJECTIVE
  The renin-angiotensin-aldosterone system has become known as a prerequisite for tumor angiogenesis that is now recognized as a crucial step in the development of tumors, including cervical cancer. The Ang II-AT1R pathway is known to play an important role in tumor angiogenesis. MicroRNAs (miRNAs) are a class of small, regulating RNAs that participate in tumor genesis, differentiation and proliferation. The current study focused on the anti-tumor mechanism of olmesartan, a novel angiotensin II antagonist, on cervical cancer cells.
  
  
  METHODS
  qRT-PCR and Western blot were used to demonstrate the effect of olmesartan on miR-205 and VEGF-A expression. miR-205 mimics and VEGF-A shRNA plasmid were separately transfected into HeLa and Siha cells to further validate the function of miR-205 and VEGF-A in cervical cancer cell proliferation.
  
  
  RESULTS
  It was found that olmesartan could upregulate miR-205 and inhibit VEGF-A expression in HeLa and Siha cells. In addition, VEGF-A was proven to be a target gene of miR-205.
  
  
  CONCLUSIONS
  This result provides a new idea on the anti-tumor mechanism of olmesartan, which may be used as a novel therapeutic target of cervical cancer.
authors.affiliation: 1 Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300052, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yue
authors.affiliation: 2 Departments of Gynecology and Obstetrics,Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Zhang
authors.initials: Z
authors.lastname: Yun-Shan
authors.affiliation: 1 Tianjin Central Hospital of Gynecology Obstetrics, Tianjin 300052, China.
authors.forename: Xue
authors.initials: X
authors.lastname: Feng-Xia
mesh_terms: D000804:Angiotensin II; D001483:Base Sequence; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D009361:Neoplasm Invasiveness; D009841:Oligonucleotides / Q000378:metabolism; D013777:Tetrazoles / Q000494:pharmacology*; D014410:Tumor Stem Cell Assay; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: D000804:Angiotensin II; D007093:Imidazoles; D035683:MicroRNAs; D009841:Oligonucleotides; D013777:Tetrazoles; D042461:Vascular Endothelial Growth Factor A; C534425:MIR205, human; C477371:locked nucleic acid; C437965:olmesartan
keywords: Olmesartan; VEGF-A; cervical cancer; miR-205; proliferation